CPB2 and cardiovascular disorder: Depending on its partial elimination of Arg, which is meant to be recognized by fibrinolysin, two pathways, namely interference with TAFI activation and the direct inhibition of TAFI, are indicated as promising pharmacological strategies for the treatment of thrombosis and cardiovascular diseases [18,19,20,21].